Who Paid My Doc
BI 754091 first-in-man dose escalation
Research payments
$1,524,045
Through program year 2024, $1,524,045 in research payments was reported against BI 754091 first-in-man dose escalation, across 560 payments, paid by Boehringer Ingelheim International GmbH.
- Paid by
- Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $6,893 | 2 |
| 2021 | Research | $168,568 | 123 |
| 2020 | Research | $436,363 | 227 |
| 2019 | Research | $912,221 | 208 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Melissa Johnson Nashville, TN Named on 224 payments
- Manish Patel Sarasota, FL Named on 145 payments
- Ulka Vaishampayan Ann Arbor, MI Named on 84 payments
- Raid Aljumaily Greenville, NC Named on 66 payments
- Ira Winer Detroit, MI Named on 15 payments
- Mark Kozloff Harvey, IL Named on 11 payments
- Siqing Fu Houston, TX Named on 9 payments
- Monica Mita San Antonio, TX Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.